Loss-of-function experiments demonstrate that SERPINB5 depletion sensitizes cervical cancer cells to paclitaxel and vincristine, while its reintroduction restores chemoresistance even in m<sup>5</sup>C-deficient cells. This evidence concerns the gene SERPINB5 and cervical cancer.